M&A Deal Summary

Arsenal Capital Partners Acquires CellCarta

On July 31, 2019, private equity firm Arsenal Capital Partners acquired life science company CellCarta from GHO Capital Partners

Acquisition Highlights
  • This is Arsenal Capital Partners’ 5th transaction in the Life Science sector.
  • This is Arsenal Capital Partners’ 1st transaction in Canada.
  • This is Arsenal Capital Partners’ 1st transaction in Quebec.

M&A Deal Summary
Date 2019-07-31
Target CellCarta
Sector Life Science
Buyer(s) Arsenal Capital Partners
Sellers(s) GHO Capital Partners
Deal Type Secondary Buyout

Target

CellCarta

Montreal, Quebec, Canada
CellCarta is a provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials. CellCarta was founded in 2000 and is based in Montreal, Quebec.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Arsenal Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 10.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Arsenal Capital Partners is a private equity firm focused on middle-market healthcare, specialty industrial, and financial service companies. Specifically, Arsenal looks to acquire businesses in the areas of specialty chemicals, aerospace/defense, transportation, environmental services, business services, insurance, asset management, financial technology, medical products, healthcare IT, and healthcare contract research/manufacturing. The Firm typically seeks to commit $50 to $300 million per investment in profitable businesses with at least $10 million of EBITDA. Funds are generally used to support buyouts, recapitalizations, growth financings, consolidations, and divestitures. The Firm avoids investing in companies reliant on high levels of technology. Arsenal Capital Partners was formed in 2000 and is headquartered in New York City.

DEAL STATS #
Overall 44 of 57
Sector (Life Science) 5 of 6
Type (Secondary Buyout) 9 of 15
State (Quebec) 1 of 1
Country (Canada) 1 of 2
Year (2019) 6 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-30 Seal For Life Industries

Stadskanaal, Netherlands

Seal For Life Industries is a provider of corrosion prevention, waterproofing, and insulation prodStadskanaalucts. offers products for various markets, such as marine, splash zone, and underwater installation, mobile pipeline coating, onshore oil and gas pipelines, offshore, insulation, casing filler, energy, flooring, refinery, cathodic protection, cables and wires, and wastewater. Seal For Life Industries was founded in 1988 and is based in Stadskanaal, Netherlands.

Buy $328M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-18 Spartech

St. Louis, Missouri, United States

Spartech is a producer of plastic products including polymeric compounds, concentrates, custom extruded sheet and roll stock products, and packaging solutions for a wide spectrum of customers. Spartech was founded in 1960 and is based in St. Louis, Missouri.

Sell -

Seller(S) 1

SELLER

GHO Capital Partners

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2014
PE ASSETS 6.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

GHO Capital Partners is a private investment firm focused on the healthcare sector. The Firm will consider opportunities throughout Europe and seeks well-established, profitable businesses that have the potential to deliver a combination of double-digit top line growth, significant efficiency gains and international expansion. GHO Capital Partners was established in 2014 and is based in London, England.

DEAL STATS #
Overall 2 of 4
Sector (Life Science) 2 of 4
Type (Secondary Buyout) 1 of 2
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2019) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-18 Quotient Sciences

Nottingham, United Kingdom

Quotient Sciences is a provider of outsourced, early-stage drug development services to the pharmaceutical industry. Quotient Sciences has brought innovation to the pharmaceutical services sector through its unique Translational Pharmaceutics® platform, which is proven to accelerate development timelines, reduce development costs, and drive improvement in R&D productivity. Quotient Sciences is based in Nottingham, England.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-09 Ardena

Mariakerke, Belgium

Ardena is a contract development and manufacturing organization (CDMO). Ardena offers an integrated, flexible service encompassing drug substance production, dosage form manufacture, clinical logistics, bioanalysis, and dossier development. Ardena was founded in 1994 and is based in Mariakerke, Belgium.

Buy -
Mergr

Product

Company

Legal